Samsung BioLogics terminates MSA with CytoDyn effective Jan 5, 2024; company has sufficient leronlimab for trials

CytoDyn Inc.

Samsung informed CytoDyn on Nov 21, 2023 of intent to terminate MSA effective Jan 5, 2024.
Agreement from April 2019 covered tech transfer, manufacturing, vial filling, and supply for leronlimab.
Samsung paused manufacturing for all unfulfilled commitments in January 2022.
CytoDyn states it holds sufficient leronlimab for short-term prospective clinical trials.
Company plans to continue resolving outstanding issues including breach notice, payment schedule, and extended manufacturing postponement.

item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CytoDyn Inc. terminated Master Services Agreement with Samsung BioLogics Co., Ltd. (effective 2023-11-21).

Action: termination
Agreement: supply
Counterparty: Samsung BioLogics Co., Ltd.
Effective: 2023-11-21

Exact text from the filing

On November 21, 2023, Samsung BioLogics Co., Ltd. (“Samsung”), informed CytoDyn Inc., a Delaware corporation (the “Company”), of Samsung’s intent to terminate, effective January 5, 2024, the Master Services Agreement (the “Agreement”) entered into between Samsung and the Company in April 2019.

View on SEC.gov

44 material agreements filed in the last 30 days. Browse all material agreements →

CytoDyn Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-019363

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.